Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TSHA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.28
vs -1.31
Q2.23
N/A
-0.38
vs -0.84
Q3.23
N/A
-0.13
vs -0.64
Q4.23
+135%
0.35
vs -0.99
Q1.24
N/A
-0.10
vs -0.28
Q2.24
N/A
-0.09
vs -0.38
Q3.24
N/A
-0.09
vs -0.13
Q4.24
N/A
-0.07
vs 0.35
Q1.25
N/A
-0.09
vs -0.10
Q2.25
N/A
-0.09
vs -0.09
Sales Growth
YoY
Current
Estimates
Q1.23
NA
4.7M vs NA
Q2.23
NA
2.4M vs NA
Q3.23
NA
4.7M vs NA
Q4.23
+44%
3.6M vs 2.5M
Q1.24
-28%
3.4M vs 4.7M
Q2.24
-54%
1.1M vs 2.4M
Q3.24
-62%
1.8M vs 4.7M
Q4.24
-44%
2M vs 3.6M
Q1.25
-45%
1.9M vs 3.4M
Q2.25
+97%
2.2M vs 1.1M
Return on Equity
QoQ
Q1.23
+134%
1.34
vs -61.18
Q2.23
+66%
0.66
vs 1.34
Q3.23
+238%
2.38
vs 0.66
Q4.23
+64%
0.64
vs 2.38
Q1.24
-45%
-0.45
vs 0.64
Q2.24
-19%
-0.19
vs -0.45
Q3.24
-29%
-0.29
vs -0.19
Q4.24
-26%
-0.26
vs -0.29
Institutionnal Ownership
QoQ
Q1.23
44
44
vs 53
-17%
Q2.23
39
39
vs 44
-11%
Q3.23
64
64
vs 39
64%
Q4.23
89
89
vs 64
39%
Q1.24
111
111
vs 89
25%
Q2.24
107
107
vs 111
-4%
Q3.24
120
120
vs 107
12%
Q4.24
128
128
vs 120
7%
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
nypost.com
14 hours ago
globenewswire.com
16 hours ago
Forecast
191%2025-Revenue
-364%2025-EPS
94%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
BMO Capital
initialisePrevious: Not converted
2024-06-26
Now: Outperform
Jefferies
upgradePrevious: Not converted
2024-05-14
Now: Buy
Piper Sandler
initialisePrevious: Not converted
2024-04-09
Now: Overweight
BTIG
downgradePrevious: Not converted
2023-02-02
Now: Neutral
Quote Panel
Key Metrics
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.20Â ( 10.53%)
Pre-market 2.08$-0.02 (-0.95%)
Relative Strenght
87
Volume Buzz
169%
Earning Acce
No
Dist 52w H.
51%Relative Strength
TSHA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|